Work

PROCLAIM-001: A first-in-human trial to assess tolerability of the protease-activatable anti-PD-L1 Probody CX-072 in solid tumors and lymphomas.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps3107

Authors: Alexander I. Spira, Mark R. Middleton, Aung Naing, Karen A. Autio, John J. Nemunaitis, Johanna C. Bendell, Michael Gordon, Rachel W. Humphrey, Chihunt Wong, Naiyer A. Rizvi

Institutions: Virginia Cancer Specialists, NIHR Oxford Biomedical Research Centre, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Mary Crowley Cancer Research Center, Tennessee Oncology, HonorHealth, CytomX Therapeutics (United States), Columbia University Irving Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892113097

Cites:

Cited by: 2

Related to: 10